Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate

ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit Hyperactivity Disorder (ADHD), may be associated with behavioral adverse effects.1 For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. [...]of the case evaluation, modified-release MPH (Medikinet) was firstly licenced in Turkey for ADHD treatment. Since none of his previous treatments were successful, the patient's ADHD medication was switched to modified-release MPH. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.